Myocardial perfusion imaging with (99 m)Tc-tetrofosmin SPECT in breast cancer patients that received postoperative radiotherapy: a case-control study

Radiat Oncol. 2011 Nov 8:6:151. doi: 10.1186/1748-717X-6-151.

Abstract

Purpose: To evaluate the cardiac toxicity of radiotherapy (RT) in breast cancer (BC) patients employing myocardial perfusion imaging (MPI) with Tc-99 m Tetrofosmin-single photon emission computer tomography (T-SPECT).

Materials and methods: We studied 46 BC female patients (28 patients with left and 18 patients with right BC) treated with postoperative RT compared to a control group of 85 age-matched females. The median time of RT to SPECT was 40 months (6-263).

Results: Abnormalities in the summed stress score (SSS) were found in 54% of left BC patients, 44.4% of right BC patients, and 32.9% of controls. In left BC patients there were significantly more SSS abnormalities compared to controls (4.0 ± 3.5 vs 2.6 ± 2.0, p = 0.05) and possible trend of increased abnormalities of right BC patients (3.7 ± 3.0 vs 2.6 ± 2.0, p = 0.14). Multiple regression analysis showed more abnormalities in the MPI of left BC patients compared to controls (SSS, p = 0.0001); Marginal toxicity was also noted in right BC patients (SSS, p = 0.045). No additional toxicity was found in patients that received adjuvant cardiotoxic chemotherapy. All T-SPECT abnormalities were clinically silent.

Conclusion: The study suggests that radiation therapy to BC patients result in MPI abnormalities but without apparent clinical consequences.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / radiotherapy*
  • Breast Neoplasms / surgery*
  • Case-Control Studies
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Middle Aged
  • Organophosphorus Compounds / pharmacology*
  • Organotechnetium Compounds / pharmacology*
  • Postoperative Period
  • Radiopharmaceuticals / pharmacology*
  • Radiotherapy / methods*
  • Risk Factors
  • Tomography, Emission-Computed, Single-Photon / methods*
  • Treatment Outcome

Substances

  • Organophosphorus Compounds
  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • technetium tc-99m tetrofosmin